Celerion is investing in its facility near Zurich

(CONNECT) Celerion is expanding its bioanalytical laboratory at its Swiss site in Fehraltdorf, near Zurich. According to a press release from the Lincoln, Nebraska-based company, this investment strengthens Celerion’s ability to meet the growing global demand for bioanalytical services, accelerate study completion, and provide access to specialised scientific expertise in complex drug development programmes. Plans call for targeted investments in state-of-the-art equipment and specialised scientific personnel.

"This expansion reflects both the growth of the bioanalytical market and the rising demand from our customers worldwide," said Dr. Chad Briscoe, Executive Vice President of Global Bioanalytical Services at Celerion. Celerion's Swiss laboratory is integrated with the company's clinical research units in the United States and the United Kingdom, which, according to the company, enables efficient sample management and the rapid delivery of high-quality data.

“As therapeutic approaches continue to evolve, our clients need bioanalytical partners who can keep pace with increasingly complex development programmes,” said Susan Thornton, who founded Celerion in 2010 and has served as its CEO ever since. "This investment ensures that we remain well-positioned to deliver the expertise, quality, and responsiveness needed to accelerate the development of new drugs." ce/mm